|
CH652145A5
(de)
|
1982-01-22 |
1985-10-31 |
Sandoz Ag |
Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
|
|
US4634666A
(en)
|
1984-01-06 |
1987-01-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Human-murine hybridoma fusion partner
|
|
IL77243A
(en)
*
|
1984-12-21 |
1996-11-14 |
Procter & Gamble |
Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
|
|
DE3521994A1
(de)
|
1985-06-20 |
1987-01-02 |
Bayer Ag |
N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4883666A
(en)
*
|
1987-04-29 |
1989-11-28 |
Massachusetts Institute Of Technology |
Controlled drug delivery system for treatment of neural disorders
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US5583112A
(en)
|
1987-05-29 |
1996-12-10 |
Cambridge Biotech Corporation |
Saponin-antigen conjugates and the use thereof
|
|
US6093406A
(en)
*
|
1988-06-02 |
2000-07-25 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccine for induction of immunity to malaria
|
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
|
US5576184A
(en)
*
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
CA2017507C
(en)
|
1989-05-25 |
1996-11-12 |
Gary Van Nest |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
|
US5196511A
(en)
*
|
1989-12-01 |
1993-03-23 |
The Scripps Research Institute |
Peptides and antibodies that inhibit integrin-ligand binding
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
DE69126304T2
(de)
|
1990-04-27 |
1997-09-04 |
Mcmichael, John, Delanson, N.Y. |
Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
|
|
US5753624A
(en)
*
|
1990-04-27 |
1998-05-19 |
Milkhaus Laboratory, Inc. |
Materials and methods for treatment of plaquing disease
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
DK0600866T3
(da)
|
1990-06-01 |
1998-03-09 |
Chiron Corp |
Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5780587A
(en)
*
|
1990-08-24 |
1998-07-14 |
President And Fellows Of Harvard College |
Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Technology Ltd. |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
EP0592668B1
(en)
|
1991-07-03 |
1999-03-10 |
Kanebo, Ltd. |
Method and device for the manufacture of a thermoplastic polyurethane elastomer
|
|
US5770358A
(en)
|
1991-09-18 |
1998-06-23 |
Affymax Technologies N.V. |
Tagged synthetic oligomer libraries
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
AU671093B2
(en)
|
1992-01-07 |
1996-08-15 |
Elan Pharmaceuticals, Inc. |
Transgenic animal models for alzheimer's disease
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5604102A
(en)
|
1992-04-15 |
1997-02-18 |
Athena Neurosciences, Inc. |
Methods of screening for β-amyloid peptide production inhibitors
|
|
US5958883A
(en)
*
|
1992-09-23 |
1999-09-28 |
Board Of Regents Of The University Of Washington Office Of Technology |
Animal models of human amyloidoses
|
|
KR100310939B1
(ko)
|
1992-10-01 |
2002-06-20 |
추후제출 |
태그로암호화한복합조합화학라이브러리
|
|
ES2156149T3
(es)
|
1992-12-04 |
2001-06-16 |
Medical Res Council |
Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
|
|
CA2115900A1
(en)
|
1993-02-22 |
1994-08-23 |
Gerald W. Becker |
Pharmaceutical screens and antibodies
|
|
WO1995006407A1
(en)
*
|
1993-08-30 |
1995-03-09 |
The Regents Of The University Of California |
Novel component of amyloid in alzheimer's disease and methods for use of same
|
|
BR9407947A
(pt)
|
1993-11-02 |
1996-11-26 |
Affymax Tech Nv |
Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
|
|
US5914349A
(en)
|
1994-01-10 |
1999-06-22 |
Teva Pharmaceutical Industries, Ltd. |
Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
|
|
US7473423B2
(en)
*
|
1994-04-29 |
2009-01-06 |
Mayo Foundation For Medical Education And Research |
Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
|
|
CA2189634A1
(en)
|
1994-05-06 |
1995-11-16 |
John J. Baldwin |
Combinatorial dihydrobenzopyran library
|
|
US5663046A
(en)
|
1994-06-22 |
1997-09-02 |
Pharmacopeia, Inc. |
Synthesis of combinatorial libraries
|
|
EP1181937A3
(en)
*
|
1994-08-09 |
2004-02-04 |
Cytrx Corporation |
Novel vaccine adjuvant and vaccine
|
|
US5589154A
(en)
*
|
1994-11-22 |
1996-12-31 |
Rutgers, The State University Of New Jersey |
Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
|
|
US5807741A
(en)
*
|
1995-07-20 |
1998-09-15 |
Brown; Douglas Richard |
Neutralizing monoclonal antibody against botulinum neurotoxin serotype F
|
|
AU5508798A
(en)
|
1996-11-19 |
1998-06-10 |
Trustees Of The University Of Pennsylvania, The |
Diagnostic and therapeutic reagents for alzheimer's disease
|
|
DK1005368T3
(da)
|
1997-03-10 |
2010-01-04 |
Ottawa Hospital Res Inst |
Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
|
|
DE69842048D1
(de)
|
1997-08-01 |
2011-01-27 |
Max Planck Gesellschaft |
Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6923964B1
(en)
*
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6913745B1
(en)
*
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US6710226B1
(en)
*
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
|
US6905686B1
(en)
*
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
DK1063294T3
(da)
|
1998-02-09 |
2006-05-22 |
Boehringer Ingelheim Int |
DNA'er eller gener der deltager i Parkinsons sygdom
|
|
AU3117799A
(en)
*
|
1998-03-30 |
1999-10-18 |
Trustees Of The University Of Pennsylvania, The |
Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
|
|
DE69942274D1
(de)
|
1998-05-21 |
2010-06-02 |
Univ Tennessee Res Foundation |
Methoden zur amyloidentfernung mit anti-amyloid-antikörper
|
|
US6184351B1
(en)
*
|
1998-09-25 |
2001-02-06 |
Amgen Inc. |
α-synuclein super-mutants accelerate α-synuclein aggregation
|
|
DE69940024D1
(de)
|
1998-10-06 |
2009-01-15 |
Univ California |
Methode zum screening von anti-amyloidogenen eigenschaften und methode zur behandlung neurodegenerativer krankheiten
|
|
US6172122B1
(en)
*
|
1998-12-17 |
2001-01-09 |
The Lubrizol Corporation |
Stable emulsions from gelled overbased substrates with surfactants and aqueous liquids
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
US20040146521A1
(en)
*
|
1999-06-01 |
2004-07-29 |
Schenk Dale B. |
Prevention and treatment of synucleinopathic disease
|
|
EP1204674A4
(en)
*
|
1999-07-27 |
2005-06-01 |
Abgenix Inc |
METHODS AND COMPOUNDS FOR PREVENTING POLYPEPTIDE COLLECTIONS ASSOCIATED WITH NEUROLOGICAL DISORDERS
|
|
GB9924513D0
(en)
*
|
1999-10-15 |
1999-12-15 |
Novartis Ag |
Organic compounds
|
|
US20020094335A1
(en)
*
|
1999-11-29 |
2002-07-18 |
Robert Chalifour |
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
|
|
WO2001053457A2
(en)
|
2000-01-21 |
2001-07-26 |
University Of Connecticut Health Center |
Vaccines against neurodegenerative disorders
|
|
US7276643B2
(en)
|
2000-02-18 |
2007-10-02 |
The Regents Of The University Of California |
Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
|
|
JP5025871B2
(ja)
*
|
2000-02-21 |
2012-09-12 |
エイチ．リュンドベック エイ／エス |
アミロイドの新規なダウン−レギュレート方法
|
|
AU783144B2
(en)
*
|
2000-02-21 |
2005-09-29 |
H. Lundbeck A/S |
Novel method for down-regulation of amyloid
|
|
AU4819101A
(en)
|
2000-04-13 |
2001-10-30 |
University Of British Columbia, The |
Modulating cell survival by modulating huntingtin function
|
|
US6784291B2
(en)
*
|
2000-05-04 |
2004-08-31 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
WO2002004482A1
(en)
*
|
2000-07-07 |
2002-01-17 |
Panacea Pharmaceuticals, Inc. |
Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
|
|
CA2414772C
(en)
|
2000-07-07 |
2011-06-28 |
Jan Naslund |
Prevention and treatment of alzheimer's disease
|
|
PE20020574A1
(es)
*
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
WO2002050121A1
(fr)
*
|
2000-12-13 |
2002-06-27 |
Taisho Pharmaceutical Co.,Ltd. |
Nouvel anticorps
|
|
WO2002059621A2
(en)
*
|
2001-01-24 |
2002-08-01 |
Bayer Corporation |
Regulation of transthyretin to treat obesity
|
|
US6815175B2
(en)
*
|
2001-03-16 |
2004-11-09 |
Cornell Research Foundation, Inc. |
Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
|
|
WO2003000714A2
(en)
|
2001-06-22 |
2003-01-03 |
Panacea Pharmaceuticals, Inc. |
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
|
MY144532A
(en)
*
|
2001-08-20 |
2011-09-30 |
Lundbeck & Co As H |
Novel method for down-regulation of amyloid
|
|
EP1451217A4
(en)
*
|
2001-11-20 |
2005-10-12 |
Atgen Co Ltd |
NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
|
|
EP1572894B1
(en)
*
|
2001-11-21 |
2016-04-13 |
New York University |
Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
|
|
GB0203446D0
(en)
*
|
2002-02-14 |
2002-04-03 |
Univ Lancaster |
Detection and/or monitoring of synuclein-related diseases
|
|
GB0216972D0
(en)
|
2002-07-22 |
2002-08-28 |
Univ Lancaster |
Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
|
|
AU2003287015A1
(en)
*
|
2002-09-30 |
2004-04-23 |
Auburn University |
Method of isolation and self-assembly of small protein particles from blood and other biological materials
|
|
US20080014194A1
(en)
*
|
2003-10-31 |
2008-01-17 |
Elan Pharmaceuticals, Inc. |
Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
|
|
US8697082B2
(en)
*
|
2002-11-01 |
2014-04-15 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
TW200509968A
(en)
*
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
|
US9034337B2
(en)
*
|
2003-10-31 |
2015-05-19 |
Prothena Biosciences Limited |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
|
|
US8506959B2
(en)
*
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
PL2361928T3
(pl)
*
|
2003-05-19 |
2017-09-29 |
Prothena Biosciences Limited |
Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
|
|
US7358331B2
(en)
*
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
|
WO2005047860A2
(en)
*
|
2003-11-08 |
2005-05-26 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
|
US20050203010A1
(en)
*
|
2003-11-14 |
2005-09-15 |
Atgen Co., Ltd. |
Novel peptides conferring environmental stress resistance
and fusion proteins including said peptides
|
|
EA013752B1
(ru)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
|
|
WO2007011907A2
(en)
|
2005-07-19 |
2007-01-25 |
University Of Rochester |
Alpha-synuclein antibodies and methods related thereto
|
|
WO2007021255A1
(en)
|
2005-08-09 |
2007-02-22 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
|
US8147833B2
(en)
*
|
2007-02-23 |
2012-04-03 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
|
PL2583978T3
(pl)
|
2007-02-23 |
2016-07-29 |
Prothena Biosciences Ltd Co |
Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
|